Optimized second-generation mRNA vaccine demonstrated improved protection against COVID-19 in preclinical testing

Researchers conducted a head-to-head test of the second-generation vaccine CV2CoV compared with CVnCoV. The scientists assessed the vaccines' ability to provoke an immune response as well as their protective efficacy against COVID-19 in non-human primates.